The role of biopsy pathology, quantitative nuclear morphometry, and biomarkers in the preoperative prediction of prostate cancer staging and prognosis - PubMed (original) (raw)
Affiliations
- PMID: 9741414
Review
The role of biopsy pathology, quantitative nuclear morphometry, and biomarkers in the preoperative prediction of prostate cancer staging and prognosis
R W Veltri et al. Semin Urol Oncol. 1998 Aug.
Abstract
The focus of this review is to survey pretreatment biopsy and patient-derived information applicable to predicting pathological stage and prognosis of men with a diagnosis of prostate cancer. Various sources of clinical and pathological information that may contribute to building decision support tools (DSTs) for application by the urologist to manage prostate cancer patients are presented. These DSTs use serum biomarkers and objective, well-established, pathology information extracted by experienced pathologists from needle-core tissue samples that describe tumor size, grade, and location. Other valuable data can be derived from the biopsy tissue, such as computer-assisted image cytometry-derived DNA ploidy and nuclear morphometry informatics, as well as select tissue biomarker results that may provide supplemental prognostic information. Also discussed are the technical and clinical limitations of these DSTs with respect to the prediction accuracy. A commercially available pretreatment prediction algorithm (UroScore, Oklahoma City, OK) was applied to predict the disease organ confinement status of the prostate cancer test case. Finally, the authors present existing and future applications of computer-derived computational solutions for incorporating all patient history, clinical laboratory, and pathology information into algorithms that can generate patient-specific predictive probability estimates of stage, recurrence, and progression.
Similar articles
- Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
Veltri RW, Miller MC, Mangold LA, O'Dowd GJ, Epstein JI, Partin AW. Veltri RW, et al. J Urol. 2002 Jul;168(1):100-4. J Urol. 2002. PMID: 12050500 - Prediction of prostate-specific antigen recurrence in men with long-term follow-up postprostatectomy using quantitative nuclear morphometry.
Veltri RW, Miller MC, Isharwal S, Marlow C, Makarov DV, Partin AW. Veltri RW, et al. Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):102-10. doi: 10.1158/1055-9965.EPI-07-0175. Cancer Epidemiol Biomarkers Prev. 2008. PMID: 18199716 - Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy.
Villamón-Fort R, Martínez-Jabaloyas JM, Soriano-Sarriá P, Ramos-Soler D, Pastor-Hernández F, Gil-Salom M. Villamón-Fort R, et al. Urol Int. 2007;78(4):328-33. doi: 10.1159/000100837. Urol Int. 2007. PMID: 17495491 - Prognostic value of serum markers for prostate cancer.
Stenman UH, Abrahamsson PA, Aus G, Lilja H, Bangma C, Hamdy FC, Boccon-Gibod L, Ekman P. Stenman UH, et al. Scand J Urol Nephrol Suppl. 2005 May;(216):64-81. doi: 10.1080/03008880510030941. Scand J Urol Nephrol Suppl. 2005. PMID: 16019759 Review. - Prostate biopsy: who, how and when. An update.
Djavan B, Milani S, Remzi M. Djavan B, et al. Can J Urol. 2005 Feb;12 Suppl 1:44-8; discussion 99-100. Can J Urol. 2005. PMID: 15780165 Review.
Cited by
- Nuclear Morphometric Analysis of Leydig Cells of Male Pubertal Rats Exposed In Utero to Di(n-butyl) Phthalate.
Wakui S, Motohashi M, Satoh T, Shirai M, Mutou T, Takahashi H, Wempe MF, Endou H, Inomata T, Asari M. Wakui S, et al. J Toxicol Pathol. 2013 Dec;26(4):439-46. doi: 10.1293/tox.2013-0031. Epub 2013 Dec 26. J Toxicol Pathol. 2013. PMID: 24526819 Free PMC article. Retracted. - p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape.
Isharwal S, Miller MC, Marlow C, Makarov DV, Partin AW, Veltri RW. Isharwal S, et al. Prostate. 2008 Jul 1;68(10):1097-104. doi: 10.1002/pros.20772. Prostate. 2008. PMID: 18459105 Free PMC article. - Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy.
Isharwal S, Miller MC, Epstein JI, Mangold LA, Humphreys E, Partin AW, Veltri RW. Isharwal S, et al. Int J Cancer. 2008 Dec 1;123(11):2636-43. doi: 10.1002/ijc.23838. Int J Cancer. 2008. PMID: 18767043 Free PMC article. - DNA Ploidy as surrogate for biopsy gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction.
Isharwal S, Miller MC, Epstein JI, Mangold LA, Humphreys E, Partin AW, Veltri RW. Isharwal S, et al. Urology. 2009 May;73(5):1092-7. doi: 10.1016/j.urology.2008.09.060. Epub 2009 Feb 3. Urology. 2009. PMID: 19193410 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical